Improved outcome after relapse in children with acute myeloid leukaemia
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Abrahamsson, JonasClausen, Niels
Gustafsson, Göran
Hovi, Liisa
Jonmundsson, Gudmundur
Zeller, Bernward
Forestier, Erik
Heldrup, Jesper
Hasle, Henrik
Issue Date
2007-01-01
Metadata
Show full item recordCitation
Br. J. Haematol. 2007, 136(2):229-236Abstract
In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2141.2006.06419.x
Scopus Count
Collections
Related articles
- Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
- Authors: Karlsson L, Forestier E, Hasle H, Jahnukainen K, Jónsson ÓG, Lausen B, Norén Nyström U, Palle J, Tierens A, Zeller B, Abrahamsson J
- Issue date: 2017 Aug
- Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
- Authors: Nakayama H, Tomizawa D, Tanaka S, Iwamoto S, Shimada A, Saito AM, Yamashita Y, Moritake H, Terui K, Taga T, Matsuo H, Kosaka Y, Koh K, Hosoi H, Kurosawa H, Isoyama K, Horibe K, Mizutani S, Adachi S
- Issue date: 2017 Oct
- Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
- Authors: Park H, Youk J, Kim I, Yoon SS, Park S, Lee JO, Bang SM, Koh Y
- Issue date: 2016 Oct
- Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
- Authors: Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M
- Issue date: 2009 Aug
- The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
- Authors: Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ
- Issue date: 2009 Jun